Recombinant
human erythropoetin (EPO) is an important biopharmaceutical
mainly used for the treatment of anemia. It is highly heterogeneous
because of common amino acid chemical degradations known to occur
in protein therapeutics (e.g., oxidation and deamidation)
and its complex glycosylation profile. Recently, multi-attribute monitoring
(MAM), i.e., the quantification of multiple post-translational
and chemical modifications in a single peptide mapping liquid chromatography–mass
spectrometry (LC-MS)-based method, has received increased attention
for the analysis of antibody-like biotherapeutic proteins. In this
study, an MAM method for examination of residue-specific glycan profiles
of EPO was established. The MAM method, by virtue of the increased
sensitivity and selectivity provided with LC-MS, yielded additional
site-specific information not afforded by the conventional quality
control (QC) methods. Low abundant glycans as well as additional post-translational
and chemical modifications could also be simultaneously detected by
the MAM method. Our results demonstrate that desialylated N-oligosaccharides (DeNO) and N-acetylneuraminic
acids (Neu5Ac) could be monitored by the developed MAM approach with
data readout highly comparable to QC methods, while differences were
observed for charge isoform distribution. In summary, the comparative
data obtained demonstrate that MAM by LC-MS peptide mapping can, in
principle, adequately replace selected QC methods and would add value
to the in-process control and release testing strategy of EPO.